Literature DB >> 17507233

Synthesis of sialic acid derivatives as ligands for the myelin-associated glycoprotein (MAG).

Sachin V Shelke1, Gan-Pan Gao, Stefanie Mesch, Heiko Gäthje, Soerge Kelm, Oliver Schwardt, Beat Ernst.   

Abstract

The trisaccharide substructure 13 of the ganglioside GQ1balpha shows a remarkable affinity for the myelin-associated glycoprotein (MAG). In the search for structurally simplified and pharmacokinetically improved mimics of 13, sialosides with modifications at the reducing and non-reducing end were synthesized. The biological evaluation of mimics 12a-o was performed in a competitive target-based assay. It was found that the relative inhibitory potency (rIP) of antagonist 12h was enhanced by more than 1000-fold in comparison to the reference trisaccharide 13, despite the former having a much simpler structure. In addition, the sialic acid derivatives, for example, 12h, have clearly improved pharmacokinetic properties due to the presence of aromatic moieties, a lower molecular weight, and a reduced number of polar hydroxy functions compared to the reference compound 13.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17507233     DOI: 10.1016/j.bmc.2007.04.038

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  10 in total

Review 1.  The chemical neurobiology of carbohydrates.

Authors:  Heather E Murrey; Linda C Hsieh-Wilson
Journal:  Chem Rev       Date:  2008-05-02       Impact factor: 60.622

2.  High affinity sialoside ligands of myelin associated glycoprotein.

Authors:  Ying Zeng; Christoph Rademacher; Corwin M Nycholat; Satoshi Futakawa; Katrin Lemme; Beat Ernst; James C Paulson
Journal:  Bioorg Med Chem Lett       Date:  2011-04-23       Impact factor: 2.823

3.  CD22-antagonists with nanomolar potency: the synergistic effect of hydrophobic groups at C-2 and C-9 of sialic acid scaffold.

Authors:  Hajjaj H M Abdu-Allah; Kozo Watanabe; Gladys C Completo; Magesh Sadagopan; Koji Hayashizaki; Chiaki Takaku; Taichi Tamanaka; Hiromu Takematsu; Yasunori Kozutsumi; James C Paulson; Takeshi Tsubata; Hiromune Ando; Hideharu Ishida; Makoto Kiso
Journal:  Bioorg Med Chem       Date:  2011-02-02       Impact factor: 3.641

Review 4.  Therapeutic Targeting of Siglecs using Antibody- and Glycan-Based Approaches.

Authors:  Takashi Angata; Corwin M Nycholat; Matthew S Macauley
Journal:  Trends Pharmacol Sci       Date:  2015-10       Impact factor: 14.819

Review 5.  Chemical priming for spinal cord injury: a review of the literature part II-potential therapeutics.

Authors:  Martin M Mortazavi; Ketan Verma; Aman Deep; Fatemeh B Esfahani; Patrick R Pritchard; R Shane Tubbs; Nicholas Theodore
Journal:  Childs Nerv Syst       Date:  2010-12-21       Impact factor: 1.475

Review 6.  Chemical priming for spinal cord injury: a review of the literature. Part I-factors involved.

Authors:  Martin M Mortazavi; Ketan Verma; Aman Deep; Fatemeh B Esfahani; Patrick R Pritchard; R Shane Tubbs; Nicholas Theodore
Journal:  Childs Nerv Syst       Date:  2010-12-18       Impact factor: 1.475

7.  Sialoside analogue arrays for rapid identification of high affinity siglec ligands.

Authors:  Ola Blixt; Shoufa Han; Liang Liao; Ying Zeng; Julia Hoffmann; Satoshi Futakawa; James C Paulson
Journal:  J Am Chem Soc       Date:  2008-05-02       Impact factor: 15.419

8.  Acetylated hyaluronic acid: enhanced bioavailability and biological studies.

Authors:  Carmela Saturnino; Maria Stefania Sinicropi; Ortensia Ilaria Parisi; Domenico Iacopetta; Ada Popolo; Stefania Marzocco; Giuseppina Autore; Anna Caruso; Anna Rita Cappello; Pasquale Longo; Francesco Puoci
Journal:  Biomed Res Int       Date:  2014-07-08       Impact factor: 3.411

Review 9.  Siglec Ligands.

Authors:  Anabel Gonzalez-Gil; Ronald L Schnaar
Journal:  Cells       Date:  2021-05-20       Impact factor: 6.600

Review 10.  From carbohydrate leads to glycomimetic drugs.

Authors:  Beat Ernst; John L Magnani
Journal:  Nat Rev Drug Discov       Date:  2009-07-24       Impact factor: 84.694

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.